Neoadjuvant radiotherapy with or without PD-1 inhibitor (Camrelizumab) for resectable hepatocelluar carcinoma with portal vein tumor thrombus: a randomized multicenter controlled study
Latest Information Update: 04 Aug 2020
Price :
$35 *
At a glance
- Drugs Camrelizumab (Primary)
- Indications Liver cancer
- Focus Therapeutic Use
- 04 Aug 2020 New trial record